What is Optina Diagnostics?
Optina Diagnostics, based in Montreal, is at the forefront of revolutionizing brain health and the diagnosis of systemic diseases. The company's primary focus is on the early detection of Alzheimer's disease, challenging conventional diagnostic methods. Optina offers a non-invasive, optical testing solution designed to accurately identify age-related causes of memory loss. This innovative technology aims to empower millions by providing a simpler and more accessible pathway to understanding cognitive decline.
How much funding has Optina Diagnostics raised?
Optina Diagnostics has raised a total of $22.1M across 2 funding rounds:
Series A
$20M
Unspecified
$2.1M
Series A (2021): $20M with participation from Desjardins Capital, DigitalDx Ventures, Boehringer Ingelheim Venture Fund, and Hike Ventures
Unspecified (2022): $2.1M led by Alzheimer's Drug Discovery Foundation
Key Investors in Optina Diagnostics
Desjardins Capital
Desjardins Capital is an investment fund focused on supporting small and medium-sized enterprises in Quebec, indicating a strategic interest in regional economic development and established growth companies.
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund invests in pioneering science and disease-modifying therapeutics, suggesting a focus on innovative healthcare solutions and early-stage biotechnology with significant therapeutic potential.
Alzheimer's Drug Discovery Foundation
The Alzheimer's Drug Discovery Foundation (ADDF) is a not-for-profit organization dedicated to accelerating the development of drugs for Alzheimer's disease, highlighting a commitment to advancing research and therapeutic interventions for neurodegenerative conditions.
What's next for Optina Diagnostics?
The recent major strategic investment positions Optina Diagnostics for accelerated growth and market penetration. This capital infusion is expected to fuel further research and development, enhance the company's diagnostic platform, and expand its reach to a broader patient population. With a clear focus on Alzheimer's and other age-related neurological conditions, Optina is poised to become a key player in the global brain health sector, driving innovation in diagnostic accuracy and patient care.
See full Optina Diagnostics company page
